These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25424701)

  • 1. Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer.
    Lend AK; Kazantseva A; Kivil A; Valvere V; Palm K
    Tumour Biol; 2015 Apr; 36(4):2473-80. PubMed ID: 25424701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
    Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
    Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
    Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
    Tanić M; Krivokuća A; Čavić M; Mladenović J; Plesinac Karapandžić V; Beck S; Radulović S; Susnjar S; Janković R
    Radiat Oncol; 2018 Oct; 13(1):193. PubMed ID: 30285791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
    Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Jiang YZ; Huang L; Zhou RJ; Yu KD; Liu Y; Shao ZM
    Clin Cancer Res; 2013 Dec; 19(24):6853-62. PubMed ID: 24141623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.
    Talieri M; Devetzi M; Scorilas A; Pappa E; Tsapralis N; Missitzis I; Ardavanis A
    Tumour Biol; 2012 Aug; 33(4):1075-84. PubMed ID: 22351561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.
    Fici P; Gallerani G; Morel AP; Mercatali L; Ibrahim T; Scarpi E; Amadori D; Puisieux A; Rigaud M; Fabbri F
    Oncotarget; 2017 Jan; 8(2):2423-2436. PubMed ID: 27911856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
    Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
    Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
    Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
    Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression.
    Pospisil H; Herrmann A; Butherus K; Pirson S; Reich JG; Kemmner W
    BMC Genomics; 2006 Jun; 7():148. PubMed ID: 16772034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer.
    Aljada A; Doria J; Saleh AM; Al-Matar SH; AlGabbani S; Shamsa HB; Al-Bawab A; Ahmed AA
    Cell Oncol (Dordr); 2016 Apr; 39(2):161-74. PubMed ID: 26732077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.
    Ma G; Huang H; Li M; Li L; Kong P; Zhu Y; Xia T; Wang S
    Cancer Biomark; 2018; 22(3):405-415. PubMed ID: 29758926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
    Tanaka N; Yoshida H; Suzuki Y; Harigaya K
    Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
    Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
    Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy.
    Yalcin B
    Exp Oncol; 2013 Dec; 35(4):250-2. PubMed ID: 24382433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional expression analysis of survivin splice variants reveals differential expression of survivin-3α in breast cancer.
    Moniri Javadhesari S; Gharechahi J; Hosseinpour Feizi MA; Montazeri V; Halimi M
    Genet Test Mol Biomarkers; 2013 Apr; 17(4):314-20. PubMed ID: 23368531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.